Status:
COMPLETED
Screening of Fabry Disease in Portuguese Patients With Idiopathic Cardiomyopathies
Lead Sponsor:
Universidade do Porto
Collaborating Sponsors:
Centro Hospitalar De São João, E.P.E.
Hospital Pedro Hispano
Conditions:
Fabry Disease
Eligibility:
All Genders
30+ years
Brief Summary
In Portugal, the prevalence of Fabry disease is largely unknown as recently has been stressed by the Portuguese hypertrophic cardiomyopathy registry investigators. On the other hand, few data on Fabr...
Eligibility Criteria
Inclusion
- Patients with heart disease diagnosed after the age of 30:
- unexplained hypertrophic cardiomyopathy (Group A)
- unexplained left ventricle hypertrophy confirmed in two different examinations using the same or different imaging methods (Group B)
- unexplained burned-out hypertrophic cardiomyopathy (Group C)
- unexplained dilated cardiomyopathy with evidence of late gadolinium enhancement involving the basal posterolateral wall segments (Group D)
Exclusion
- previous exclusion of Fabry disease
- previous identified causal pathogenic/likely pathogenic genetic variant
- evidence of cardiomyopathy under the age of 30
Key Trial Info
Start Date :
April 15 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 15 2025
Estimated Enrollment :
409 Patients enrolled
Trial Details
Trial ID
NCT05409846
Start Date
April 15 2022
End Date
April 15 2025
Last Update
October 2 2025
Active Locations (11)
Enter a location and click search to find clinical trials sorted by distance.
1
Centro Hospitalar Universitário de Coimbra
Coimbra, Portugal, 3000-602
2
Hospital da Luz, Lisboa
Lisbon, Portugal, 1500-650
3
Centro Hospitalar Universitário Lisboa Norte, EPE., Hospital de Santa Maria
Lisbon, Portugal, 1600-190
4
Hospital Pedro Hispano (Unidade Local de Saúde Matosinhos)
Matosinhos Municipality, Portugal, 4464-513